Présentation de l'entreprise

“The story of MedDay began in 2011, when Frédéric Sedel, MD, PhD, a neurologist and neuroscientist met with Guillaume Brion, an entrepreneur with experience in drug development. Both used their expertise and worked together to create MedDay, a pioneering biotechnology company with a unique approach focusing on neurometabolism.

Unfortunately, in March 2020, the second confirmatory Phase III study “SPI2” of MD1003, its lead program in Progressive Multiple Sclerosis, did not meet its primary or secondary endpoints.” from medday-pharma.com